A significant reduction in HbA1c levels in both adolescents and adults with type 1 diabetes was noted after a pivotal registration trial which evaluated the home use of Hybrid closed-loop insulin delivery system for 3 months.
The Medtronic MiniMed® 670G hybrid closed-loop insulin delivery system was found to be safe and effective, and the article was published in Diabetes Technology & Therapeutics (DTT)
‘In-home use of Hybrid closed-loop insulin delivery system was found to be safe and effective for type 1 diabetes.’
The article entitled "Glucose Outcomes with the In-home Use of a Hybrid Closed-loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes," is coauthored by Satish Garg, MD, University of Colorado Denver (Aurora) and DTT Editor-in-Chief, and a team of researchers from Yale University (New Haven, CT), Stanford University (CA), Atlanta Diabetes Associates (GA), AMCR Institute (Escondido, CA), Rainier Clinical Research Center (Renton, WA), Sheba Medical Center (Tel Hashomer, Israel), University of Virginia (Charlottesville, VA), International Diabetes Center (Minneapolis, MN), and Medtronic (Northridge, CA).
The researchers reported a significant decrease in the time participants spent in hypoglycemia and, similarly, a significant increase in the proportion of sensor glucose readings that were in the target range (71-180 mg/dL) during the study period for both adults and adolescents. Adult subjects used the system with Auto Mode (hybrid closed-loop) enabled for a median 88% of the time (>21 hrs/day). The MiniMed® 670G hybrid closed-loop system automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring.